Thrombotic antiphospholipid syndrome (APS) is clinically heterogeneous, with thrombotic manifestations spanning a broad spectrum. These encompass mild to potentially lifethreatening episodes, including refractory thrombosis despite adequate anticoagulation and the rare catastrophic APS. Thrombosis may occur in one or more of any vascular sites-venous, arterial, or microvascular.
The current mainstay of the treatment and secondary thromboprophylaxis of thrombotic APS is anticoagulation with warfarin or other vitamin K antagonists (VKAs).
1 However, treatment with VKAs is often problematic. Warfarin, the most widely used VKA worldwide, has a slow onset of action of several days, a narrow therapeutic window, numerous drug and dietary interactions, and the potential for variation of action with alcohol, intercurrent illness, exercise, and smoking. It requires regular blood test monitoring of the international normalized ratio (INR). Direct oral anticoagulants (DOACs) provide an effective, safe, and convenient therapeutic alternative to warfarin and other VKAs and are becoming the standard of care for a wide range of indications. [2] [3] [4] [5] Definition of the role of DOACs in the treatment of thrombotic APS is emerging with the results of recent and ongoing clinical studies. This review focuses on the current situation with regard to DOACs for secondary thromboprophylaxis in APS and issues pertinent to DOAC use in APS patients, as well as potential future directions.
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Abstract
The current mainstay of the treatment and secondary thromboprophylaxis of thrombotic antiphospholipid syndrome (APS) is anticoagulation with warfarin or other vitamin K antagonists (VKAs). In addition to their well-known limitations, VKAs are often problematic in APS patients because of the variable sensitivity of thromboplastins to lupus anticoagulant. As a result, the international normalized ratio may not accurately reflect the intensity of anticoagulation. Direct oral anticoagulants (DOACs) are established as therapeutic alternatives to VKAs for a wide range of indications, including the treatment and secondary prevention of venous thromboembolism. Definition of the role of DOACs in the treatment of thrombotic APS is emerging with the results of recent and ongoing clinical studies. This review focuses on the current situation with regard to DOACs for secondary thromboprophylaxis in APS and issues pertinent to DOAC use in APS patients, as well as potential future directions.
Antiphospholipid Syndrome Definition of Antiphospholipid Syndrome
APS is defined as the presence of thrombosis (venous, arterial, microvascular, or a combination of these) and/or pregnancy loss or late obstetric morbidity in association with persistently positive antiphospholipid (aPL) antibodies, that is, present on two or more occasions at least 12 weeks apart. APS may occur in isolation or in association with other conditions, notably systemic lupus erythematosus (SLE). aPL antibodies are heterogeneous, with current laboratory criteria for the diagnosis of APS based on the presence of one or more of lupus anticoagulant (LA), IgG and/or IgM anticardiolipin antibodies (aCL), and anti-β2 glycoprotein-I (aβ2GPI) antibodies. 6 
Clinical Relevance of Thrombotic Antiphospholipid Syndrome
Thrombotic APS is of major clinical relevance, particularly because thrombotic events may be potentially devastating and life threatening and it mainly affects relatively young individuals. In the Euro-Phospholipid Project with a cohort of 1,000 patients, of whom more than 70% had stroke or venous thromboembolism (VTE), the median age at study entry was 40 (range 0-82) years. 7 APS is classified as a rare disease 8 ;
however, it has been estimated that aPL antibodies are present in approximately 10% of patients with deep vein thrombosis (DVT) and 14% of all patients with stroke. 9 These are conditions that are potentially life threatening with major impact on health. Given that there are an estimated 10 million new VTE cases and 17 million new stroke cases worldwide each year, 10,11 the estimated prevalence figures may imply that APS is underdiagnosed and is more common than may be appreciated. In addition, 15% of patients with SLE have thrombotic APS, which is a major adverse prognostic factor.
12
Appropriate management of thrombotic APS is vital to minimize its deleterious impact.
Anticoagulation for Thrombotic Antiphospholipid Syndrome

Venous Thromboembolism
Retrospective studies have shown a high incidence of thrombosis recurrence in patients with aPL. [13] [14] [15] In these studies, 54% 
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It takes about 3 months to complete "active treatment" of VTE, with further treatment aimed at prevention of new episodes of thrombosis ("secondary prevention"). 17, 18 The cumulative incidence of recurrent VTE is significantly higher after an unprovoked episode, 17 and in patients with unprovoked proximal DVT or pulmonary embolism (PE), without a high risk of bleeding, extended anticoagulant therapy (no scheduled stop date) is advised by the American College of Chest Physicians (ACCP). 18 The decision to continue anticoagulation indefinitely after a first unprovoked proximal DVT or PE is strengthened if the patient is male, the index event was PE rather than DVT, and/or a raised D-dimer level 1 month after stopping anticoagulant therapy.
17,18
The paucity of robust prospective data on the influence of aPL status on VTE recurrence in patients with unprovoked or provoked VTE does not enable definitive evidence-based recommendations about whom to test for aPL after a VTE episode or the duration of anticoagulation in individuals with persistent aPL who have had an episode of VTE, unprovoked or provoked. Thrombotic APS is clinically heterogeneous, with the risk of recurrent thrombosis and intensity of anticoagulation required dependent on the clinical phenotype. A particularly high-risk group is triple aPL-positive APS patients (i.e., those who have LA, aCL, and aβ2GPI antibodies). The cumulative incidence of recurrent thrombosis, both venous and arterial, is high in such patients, 44% after 10 yearsdespite standard intensity anticoagulation (INR: 2.0-3.0).
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Untreated thrombotic APS may result in further thrombotic episodes, arterial or venous, which may be potentially life threatening or have major adverse impact on health. Identification of patients with thrombotic APS provides the opportunity to optimize management of these patients, for example, by further strengthening the decision for extended anticoagulant therapy following an unprovoked VTE episode; or by providing a basis for optimal treatment during pregnancy to potentially avoid or reduce APS-associated maternal and fetal morbidity and mortality. Clinical trials are needed to define optimal treatment strategies further in thrombotic APS patients. The identification of APS patients and definition of their clinical phenotype will enable these trials to be undertaken and maximize their applicability to APS patient subgroups. A pragmatic approach is to undertake aPL testing in all patients who have had a first unprovoked DVT or PE, with consideration of extended duration anticoagulation in all those identified to have APS. aPL testing should also be considered in patients with provoked VTE, particularly if the provoking factor for VTE appears disproportionate to the severity of the episode.
Ischemic Stroke and Cerebral Ischemic Lesions in APS Patients
Retrospective and observational studies suggest that ischemic stroke in APS patients carries a high risk of recurrence and should be treated with life-long warfarin. In a systematic review of 16 studies on secondary thromboprophylaxis in patients with aPL, 20 ten studies reported the INR measured at the time of recurrent thrombotic events. 13, 14, [21] [22] [23] [24] [25] [26] [27] In three additional studies, thrombotic events occurred only among patients who were not receiving anticoagulant treatment. 16, 28, 29 Of the 180 thrombotic events reported, 104 (57%) occurred when patients were not taking any anticoagulant or antiplatelet agent. An additional 27 events (15%), the majority arterial, occurred among patients treated with only aspirin. The remaining 49 recurrences (27%) were seen in patients treated with warfarin, whose INR at the time of the event less than 3.0 in 86% (42/49).
20
There is a lack of well-designed prospective studies to guide optimal antithrombotic treatment in APS patients with ischemic stroke or cerebral ischemic lesions. The risk of bleeding with increasing anticoagulant intensity needs to be balanced against the risk of profound permanent disability and death, or irreversible neurological deterioration as a result of recurrent stroke.
Three major prospective studies have addressed the key issue of the optimal antithrombotic treatment for stroke patients with aPL; however, these have major limitations with regard to informing definitive conclusions on the use or intensity of anticoagulation. Crowther et al 23 ; and in 25% of aCL-positive patients, the presence of IgA aCL, which is not a recommended criterion for APS diagnosis, 6 was stated to denote aPL positivity. In addition, aβ2GPI levels were not measured, so that some APS patients were not identified, as isolated aβ2GPI do occur in a proportion of APS patients, reported to be approximately 30% in one study. 32 The results of these three prospective studies do not, therefore, enable valid conclusions about the optimal antithrombotic treatment in APS, in particular in ischemic stroke patients with APS. The lack of robust data on the optimal anticoagulant intensity in ischemic stroke patients with APS is reflected in national and international guidelines: current British Committee for Standards in Haematology (BCSH) 33 This suggestion was a nongraded recommendation due to lack of consensus within the Task Force, and many physicians treating APS patients use high-intensity warfarin (target INR: 3.5) for APS patients with ischemic stroke, cerebral ischemic lesions, or arterial thrombosis in other sites.
Vitamin K Antagonists for the Treatment of Antiphospholipid Syndrome
Anticoagulation with warfarin, or other VKAs, is the current mainstay of the treatment and secondary thromboprophylaxis of thrombotic APS. VKAs may present particular problems in patients with APS. First, VKA monitoring in patients with aPL can be complicated by the variable responsiveness of thromboplastin reagents to LA, which may in turn potentially influence the validity of the prothrombin time (PT)-INR in monitoring oral VKA treatment in patients with APS. A multisite study of laboratory INR testing in patients with APS concluded that LA interference with the PT-INR measured with the majority of commercial thromboplastins is not enough to cause concern if insensitive thromboplastins, properly calibrated to assign them an instrument-specific International Sensitivity Index (ISI), are used. The investigators also suggested that new thromboplastins, especially those made of relipidated recombinant human tissue factor, should be checked to ensure that they are insensitive to the effects of aPL before they are used to monitor oral anticoagulant treatment in patients with APS. 
Direct Oral Anticoagulants
Currently available DOACs include dabigatran etexilate (Pradaxa), a direct thrombin inhibitor, and apixaban (Eliquis) as well as edoxaban (Lixiana) and rivaroxaban (Xarelto), direct factor Xa inhibitors. [2] [3] [4] [5] DOACs are established as therapeutic alternatives to VKAs, and are becoming the standard of care for a wide range of indications, detailed in the summary of product characteristics (SPC) [2] [3] [4] [5] ; these include primary thromboprophylaxis for major lower limb orthopedic surgery, the treatment and secondary prevention of VTE, the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF), and acute coronary syndromes. DOACs, in contrast to VKAs, are prescribed at a fixed dose with a more predictable effect; therefore, they do not require regular anticoagulant monitoring in the majority of clinical settings. They also have a rapid onset of action; thus, the need for bridging anticoagulation with low-molecular-weight heparin (LMWH) at the initiation of anticoagulation can often be eliminated. 3, 5 In addition, they are not affected by changes in diet and alcohol intake and have fewer drug interactions than VKAs that affect anticoagulant intensity, which would be expected to result in improved quality of life for patients. ►Table 1 summarizes the differential pharmacology and pharmacokinetics of DOACs. Safe DOAC administration requires special consideration in several populations of individuals, including those with renal or hepatic impairment, extremes of body weight, 38-40 the elderly, or those on potentially interacting medication through which DOACs are metabolized. [2] [3] [4] [5] Drug interactions and the potential for gastrointestinal (GI) bleeding are pertinent in some APS patients where an antiplatelet agent is considered in addition to anticoagulation, or in those with SLE or other autoimmune diseases, where a variety of other drugs may be considered, including nonsteroidal anti-inflammatory drugs (NSAIDs). These situations and the use of DOACs in women of childbearing potential are addressed below. Other considerations in the use of DOACs include the management of bleeding and reversal of anticoagulant effect, which are the same as for non-APS patients, and are addressed elsewhere.
41,42
Drug Interactions
One of the advantages of DOACs is that compared with VKAs such as warfarin, fewer drug interactions are believed to exist. A consequence of this, however, is that unlike VKAs, the anticoagulant effect cannot routinely be monitored when a potentially interacting drug is coprescribed. Clear contraindications exist for certain drug-drug combinations (e.g., systemic ketoconazole or itraconazole with dabigatran), while the concurrent use of other drugs should be avoided (e.g., rifampicin, carbamazepine, phenytoin It should be noted that the pivotal trials of DOAC use in NVAF and VTE treatment or prevention excluded patients thought to be at a higher risk of GI complications. Use of DOACs in daily clinical practice, often in higher-risk individuals with multiple comorbidities, would therefore be expected to influence the incidence of GI adverse events. Where possible, the additional use of drugs with known GI toxicities (e.g., NSAIDs, antiplatelets, steroids, etc.) should be avoided, but if this is not possible then a careful risk-benefit assessment is required; a potentially "lower-risk" DOAC should be selected and the dose optimized; and the coprescription of a proton pump inhibitor for gastroprotection is advised in this situation.
Direct Oral Anticoagulants in Relation to Pregnancy and Lactation
Animal studies have shown DOAC-related reproductive toxicity and secretion into milk. 5 The potential for reproductive toxicity of DOACs in humans is unknown and there are no substantive data on the use of DOACs in pregnant women via maternal or paternal exposure. Consequently, the DOAC SPCs recommend against their use in pregnancy and during breast- 53 The key recommendations can be summarized as follows: (1) women of childbearing potential should receive documented counseling prior to commencement of DOACs; (2) should pregnancy be desired, the DOAC should be switched to an alternative anticoagulant pre-conceptually, with the main alternative anticoagulant options being VKAs (to be switched to LMWH as soon as possible when pregnant and before 6 weeks of gestation), or LMWH, with cognizance that the latter may result in prolonged subcutaneous injections until pregnancy is achieved; (3) in women who become pregnant while on a DOAC, DOAC should be discontinued immediately and LMWH commenced; (4) inadvertent exposure to a DOAC would not in itself be regarded as medical grounds for termination of pregnancy-this is supported by limited pregnancy outcome data on DOAC exposure during pregnancy in 137 women 54 ;
(5) in women who become pregnant while on a DOAC and who decide to continue with pregnancy, there should be early obstetric review and fetal monitoring; (6) breast-feeding women should not be treated with DOACs. 53 The ISTH guidance on DOACs in women of childbearing potential also recommends that clinicians should collect data on the course and outcomes of pregnancy after DOAC exposure and report these to DOAC manufacturers and responsible health and regulatory authorities, to improve knowledge on potential risks and harms. All cases of DOAC exposure during pregnancy should be reported to the international ISTH registry to ensure consistency of data collection 53 : http://www.surveygizmo.com/s3/2394649/International-registry-of-pregnancy-during-NOAC-use-Inclusion.
Direct Oral Anticoagulants for Secondary Thromboprophylaxis in Patients with Antiphospholipid Syndrome
It is likely that patients with thrombotic APS were included in the study populations in the major phase 3 clinical trials of DOACs versus warfarin in patients with VTE. high-intensity anticoagulation, or in APS patients with triple aPL positivity. The anecdotal clinical reports and case series highlight the need for randomized controlled trials (RCTs) to guide the use of DOACs in thrombotic APS.
RAPS (Rivaroxaban in Antiphospholipid Syndrome) Trial
RAPS (rivaroxaban versus warfarin to treat patients with thrombotic APS, with or without SLE: a randomized, controlled, open label, phase 2/3, noninferiority) trial included APS patients on warfarin for previous VTE, target INR of 2·5 (range: 2.0-3.0; ISRCTN68222801; http://www.ucl.ac.uk/ cctu/researchareas/other/othertrials).
64,65
Participants were randomized 1:1 to warfarin or rivaroxaban 20 mg daily, at two UK hospitals, stratified by center and patient type (SLE/non-SLE). All patients had definite thrombotic APS, based on the international consensus criteria 6 and guidelines for LA testing. 32, 37 The primary outcome measure was percentage change in endogenous thrombin potential (ETP), a thrombin generation (TG) test parameter, from Direct Oral Anticoagulants for Thromboprophylaxis in APS Cohen et al. 433
randomization to day 42, with rivaroxaban noninferior if the percentage change in ETP was not more than 20% higher than for warfarin. Other TG parameters, markers of in vivo coagulation activation (prothrombin fragment F1.2, thrombinantithrombin complex and D-dimer) were also assessed, as were thrombosis and bleeding during 6 months of treatment.
Thrombin Generation
Thrombin is a pivotal component of the hemostatic mechanism, with TG via the tissue factor pathway being integral to blood coagulation. 66 The TG assay, a global assay, measures the overall tendency of a plasma sample to form thrombin after initiation of coagulation. The TG curve is quantified in terms of the lag time; time to peak TG, peak TG, and ETP, the area under the TG curve. 67 The ETP, a key parameter of TG, is derived from the end amount of free thrombin produced and incorporates all phases from activation to final endpoint.
68
In recent years, TG testing has increasingly been transformed from a research-only tool to a useful and sensitive assay for clinical use for hemophilias, 69, 70 and with the ETP identified to have predictive value for the development of recurrent VTE. [71] [72] [73] [74] TG might be an assay of particular importance in APS, as it has been shown to be informative in regard to APS status and identification of LA.
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TG testing has been used to assess the inhibitory effects of anticoagulants with the ETP demonstrated to provide a good measure of anticoagulant intensity in both patients with APS and non-APS. 77, 78 Warfarin has been shown to reduce ETP by 30 to 50%. 79, 80 Direct FXa inhibitors such as rivaroxaban can downregulate and completely suppress the process of TG in whole blood, platelet-rich plasma 81, 82 and platelet-poor plasma. 83, 84 The ETP has been shown to be an appropriate measure of the intensity of the anticoagulant effect in patients receiving rivaroxaban for VTE prophylaxis and rivaroxaban-treated healthy normal subjects 78, [85] [86] [87] ; other DOACs such as dabigatran and apixaban also inhibit TG.
88-91
RAPS Results and Conclusions
The target 116 patients were randomized. When anticoagulation intensity was assessed by percentage change in ETP alone, rivaroxaban was inferior to warfarin in patients with APS and previous VTE. However, peak TG was lower with rivaroxaban and, therefore, the overall thrombogram indicated no difference in thrombotic risk. Additionally, no new thrombotic events were seen during 6 months of treatment.
No patients had major bleeds, and the frequencies of clinically relevant and minor bleeding were similar in the two groups. The overall thrombogram and clinical outcomes suggest that APS patients with previous VTE who require standard intensity warfarin (i.e., target INR: 2·5) had no increase in thrombotic risk on rivaroxaban compared with warfarin. This conclusion was supported by in vivo coagulation activation marker concentrations being raised in only a few patients in both treatment groups. Quality-of-life assessment showed a small but significant improvement on rivaroxaban. Both rivaroxaban and warfarin inhibit TG in non-APS patients, 78 indicating effective anticoagulation. Inhibition of TG has also been shown in patients with APS when taking warfarin. 77 However, the mechanism of TG inhibition of these two agents differs: warfarin inhibits TG by reducing functional vitamin K-dependent coagulation factor levels, while rivaroxaban directly inhibits FXa through specific binding to its active site. 82, 92 Warfarin therefore affects all TG parameters equally, whereas rivaroxaban mainly affects the initiation and propagation phases of TG leading to delay in formation of the prothrombinase complex. 87 As a result, rivaroxaban induces protraction of the TG curve, which in turn results in prolongation of the lag time and time to peak TG, 78, 87 and also a relatively greater ETP than would be expected for the degree of anticoagulation with rivaroxaban. 78 This claim is depicted in ►Fig. 1 and reflected in the RAPS results. 64 The higher ETP on rivaroxaban is thus explained by altered reaction kinetics, with the overall thrombogram indicating no increase in thrombotic risk. This conclusion has been demonstrated clinically in the major phase 3 DOAC RCTs, 2-5,48-52 which are likely to have included a proportion of APS patients.
9
The ETP and peak TG findings in RAPS patients at day 42 can be attributed to anticoagulant rather than aPL effects. This claim is supported by observations that aPL effects on TG parameters under the in vitro conditions that were used in the RAPS trial are limited to prolongation of lag time and time to peak.
93 aPL could potentially interfere with the anticoagulant action of DOACs; however, we have demonstrated in in vitro studies that IgG fractions isolated from thrombotic APS patients had no effect on the anticoagulant action of rivaroxaban on TG parameters or rivaroxaban anti-Xa levels.
93
The RAPS trial was designed with a laboratory surrogate outcome measure, as this reflects the mechanism of action of the interventions in these patients. A trial with a primary end point of recurrent thrombosis would require a much larger sample size of several thousand patients, unfeasible in this patient group, with a much longer follow-up period. There was an intended selection bias: patients with VTE who developed recurrent events while on standard intensity anticoagulation and thus Fig. 1 Typical examples of thrombograms of RAPS trial patients on warfarin and rivaroxaban. The normal control thrombin generation (TG) curve has a sharp peak and short tail. Warfarin typically has a similar shape with a lower peak. However, with rivaroxaban the TG curve is protracted with a much lower peak and longer tail. RAPS required higher intensity anticoagulation were excluded, as were patients with arterial events. 64 The absence of new thrombotic events during 6 months of treatment in RAPS justifies selection of this APS subgroup and puts into context anecdotal clinical reports and case series, of recurrent thrombosis after switching APS patients from warfarin to a DOAC. Notably, almost one-third of the RAPS patient population (28%) were triple aPL positive at baseline; so, RAPS included many patients with a particularly high-risk aPL profile.
19,64
In conclusion, RAPS has shown that rivaroxaban seems efficacious and safe, and might offer a convenient alternative to warfarin in the subgroup of patients with APS who have VTE requiring standard intensity anticoagulation. 
Conclusions and Future Directions
The RAPS trial represents a major step away from the array of anecdotal data on the use of DOACs in patients with thrombotic APS. 64 Thrombotic APS is clinically heterogeneous, with the risk of recurrent thrombosis and intensity of anticoagulation being dependent on the clinical phenotype. 35 Thus, trials, such as RAPS, that involve clinically homogeneous thrombotic APS populations, who conform to internationally set definitions for APS, maximize clinical applicability for subgroups of APS patients. 64 The results of ongoing and future studies will provide further information to define the role of DOACs in thrombotic APS patients. This includes possible non-anticoagulation effects-in this regard, in a translational study on RAPS patients, we showed that complement Direct Oral Anticoagulants for Thromboprophylaxis in APS Cohen et al. 435
activation markers were elevated in anticoagulated thrombotic APS patients and decreased in APS patients who switched from warfarin to rivaroxaban. Rivaroxaban may therefore potentially provide an additional benefit to its anticoagulant effect in this patient group by limiting complement activation.
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It is important to appreciate that the major phase 3 clinical trials that established the use of DOACs versus warfarin for the treatment and secondary prevention of VTE used warfarin at a target INR of 2.5 (range: 2.0-3.0) as the comparator. It follows that the optimal intensity of DOACs in patients who experience recurrent VTE while on standard intensity VKA is not established. The RAPS trial results are not applicable to APS patients with VTE who require higher intensity anticoagulation (i.e., those with recurrent VTE while on standard intensity anticoagulation) or APS patients with stroke or other ischemic brain manifestations, or arterial thrombosis in other sites. Studies are required to define the role of DOACs, including with regard to optimal anticoagulation intensity, in these APS patient subgroups.
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